September 15, 2022 01:17 PM EDT
FDA+

No­var­tis files an­oth­er FDA pe­ti­tion to halt En­tresto com­pe­ti­tion as block­buster fight ap­proach­es

Zachary Brennan

Senior Editor

With promis­es of $5 bil­lion-plus in peak sales for No­var­tis’ En­tresto, the Swiss phar­ma is now pe­ti­tion­ing the FDA for a sec­ond time, hop­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times